Comparison of I-131 Biokinetics after Recombinant Human TSH Stimulation and Thyroid Hormone Withdrawal Measured by External Detector in Patients with Differentiated Thyroid Cancer

Kairemo, Kalevi; Kangasmäki, Aki; Bom, Hee‐Seung

doi:10.4068/cmj.2019.55.1.20

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Still, there was a reduced iodine uptake in the abdomen and kidneys during the SNA001 period compared to the THW period, which may lead to increased concentration of iodine in the sites of residual thyroid tissues and metastases ( 21 , 22 ). In addition, other evidence suggests that after rhTSH injection, iodine clearance is faster than THW ( 23 ), which may lead to a decrease in iodine retention in the background. Finally, the effect caused by low dose iodine-131 in the SNA001 administration period may lead to the decrease of iodine uptake capacity during the THW period.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma

Yang

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

SNA001 is a novel recombinant human thyroid stimulating hormone (rhTSH). rhTSH has long been approved in several countries to facilitate monitoring and ablation of thyroid carcinoma without hypothyroidism caused by thyroid hormone withdrawal (THW). To assess the safety, tolerance, pharmacokinetic and pharmacodynamic properties of SNA001, the two-period (SNA001 period and THW period), dose-ascending study in well-differentiated thyroid cancer (DTC) patients was designed. Three doses (0.45 mg, 0.9 mg, and 1.35 mg) of SNA001 were intramuscularly injected, twice in the SNA001 period to stimulate iodine-131 uptake and thyroglobulin (Tg) release. 24 h after the last dose of SNA001, iodine-131 (111–185 MBq) was administrated, followed by whole-body scan (WBS) 48 h later. THW period began just after SNA001 washout and lasted for about 3–6 weeks. When TSH level was above 30 mU/L, iodine-131 (111–185 MBq) was administrated, followed by a WBS and Tg detection 48 h later. Twenty-four DTC patients after thyroidectomy were enrolled; mean peak concentrations of SNA001 in 0.45, 0.9, and 1.35 mg groups were 18.5, 26.7, and 37.0 ng/ml (about 244.7, 354.2, and 489.6 mU/L) respectively, within 28–32 h after first dose of SNA001. SNA001 was metabolized in a dose-dependent manner. The results of WBS and Tg release in the SNA001 period were compared with those in the THW period. Compared to Tg level in baseline, the Tg levels in SNA001 and THW periods were increased, with 78% of subjects showing higher Tg levels in the THW period. 100% of the patients had concordant qualitative results of the scans within two periods in three groups. Symptoms of hypothyroidism were relieved in the SNA001 period compared with THW period, though there was no significant difference in most of the scale scores. There were no serious adverse events related to SNA001; the most common adverse events were gastrointestinal symptoms of mild and transient nature. Thus, SNA001 promises to be a safe and effective method to stimulate iodine-131 uptake and Tg secretion during monitoring and ablation for DTC without the disadvantages of incidental hypothyroidism.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma

Yang

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Kalevi et al found that recombinant human TSH stimulation (rhTSH) and thyroid hormone withdrawal (THW) could influence the I-131 biokinetics in patients with differentiated thyroid cancer, and washout of I-131 was faster after rhTSH stimulation than THW. 27 Kasner et al first found that the combination of rhTSH stimulation and nearly adequate withdrawal may help convert more I-131-negative whole-body scans to positive. 28 Cluster 5 was mainly concerned about management guidelines.…”

Section: Discussionmentioning

confidence: 99%

Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis

Shang¹,

Wei²,

Yao³

2021

IJGM

View full text Add to dashboard Cite

Background Hundreds of studies have reported the application of iodine-131 (I-131) in thyroid carcinoma (THCA) in past years. However, the status of research in the field and other related topics have not been investigated. This study aimed to identify the cooperation of authors, countries, and institutions, as well as explore the hot topics and prospects regarding I-131 therapy in THCA based on previous studies. Methods Publications from 2010 to 2020 were retrieved from Web of Science Core Collection according to research strategy. Bibliometric analyses were performed using VOSviewer 1.6.15 and CiteSpace 5.7.3 to evaluate and visualize the cooperation network, hot topic, and research frontier. Results The number of publications showed a trend of fluctuation between 2010 and 2020. We identified 1387 publications related to I-131 therapy in THCA, which were published by 1628 institutions from 82 countries. The largest proportion of publications were emanated from the USA, and the majority of papers were published by Thyroid. Shanghai Jiao Tong University of China contributed the most papers. Although many authors participated in the research of this field, high-yield authors were few. Co-occurrence analysis classified keywords into five clusters, including assessment, efficacy measurement, monitoring, hormone regulation, and guidelines of I-131 therapy. The terms “bone marrow dosimetry and time” were among the latest hotspots. The research frontier topic in I-131 therapy focused on the “P53 and anti-Müllerian hormone”. Conclusion The attention to I-131 therapy in THCA should be increased considerably. It was necessary to construct active co-operations between authors, countries, and institutions to promote the development of this field. Recent researches referred to the timing and dose assessment of I-131 therapy in THCA. Future studies likely focused on targeted therapy and adverse effects evaluation were worthy of research as well.

show abstract

Expression of NIS, VEGF-A and Thyroid Autoantibody in Papillary Thyroid Carcinoma with or without Hashimoto’s Disease

Shen

et al. 2019

ORL

View full text Add to dashboard Cite

Background: Since the incidence of papillary thyroid carcinoma (PTC) combined with Hashimoto’s thyroiditis (HT) has increased year by year, but the mechanism is still unknown, the goal of this study was to investigate the expression of Na+/I– symporter (NIS), vascular endothelial growth factor (VEGF)-A and thyroid autoantibodies in HT combined with PTC, and to explore the relationship between HT and PTC. Methods: Real-time fluorescence quantitative polymerase chain reaction was used to detect the expression of VEGF-A and NIS in 38 cases of PTC and HT combined with PTC and in 20 cases of normal tissues; preoperative serum TPOAb and TgAb levels in each group were detected by ELISA. Results: The expression of VEGF-A in PTC and HT combined with PTC was significantly higher than that in normal tissues (p < 0.05), and the expression of VEGF-A in HT combined with PTC was higher than that in PTC (p < 0.05). The expression of NIS mRNA in PTC and HT combined with PTC was significantly decreased compared to that in normal tissues (p < 0.05), and NIS mRNA in HT combined with PTC tissue was lower than that in PTC tissue (p < 0.05). The preoperative levels of TPOAb and TgAb in the HT combined with PTC group were higher than those in the normal group and the PTC group (p < 0.05). Conclusion: The presence of HT may inhibit iodine uptake and cause a decrease in NIS. Increased levels of TPOAb and TgAb in HT patients lead to a high expression of TSH and stimulate VEGF secretion. This may explain why HT could accelerate the occurrence and development of PTC.

show abstract

Comparison of I-131 Biokinetics after Recombinant Human TSH Stimulation and Thyroid Hormone Withdrawal Measured by External Detector in Patients with Differentiated Thyroid Cancer

Cited by 4 publications

References 21 publications

Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma

Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma

Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis

Expression of NIS, VEGF-A and Thyroid Autoantibody in Papillary Thyroid Carcinoma with or without Hashimoto’s Disease

Contact Info

Product

Resources

About